Michael Krainer

7.1k total citations
106 papers, 3.5k citations indexed

About

Michael Krainer is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Michael Krainer has authored 106 papers receiving a total of 3.5k indexed citations (citations by other indexed papers that have themselves been cited), including 55 papers in Oncology, 35 papers in Molecular Biology and 30 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Michael Krainer's work include Prostate Cancer Treatment and Research (22 papers), Cancer Treatment and Pharmacology (11 papers) and Cell death mechanisms and regulation (10 papers). Michael Krainer is often cited by papers focused on Prostate Cancer Treatment and Research (22 papers), Cancer Treatment and Pharmacology (11 papers) and Cell death mechanisms and regulation (10 papers). Michael Krainer collaborates with scholars based in Austria, United States and France. Michael Krainer's co-authors include Dietmar Pils, Robert Zeillinger, Peter Horak, Christoph Zielinski, Daniel A. Haber, Reinhard Horvat, E. Fritz, Kurt J. Isselbacher, Michael G. FitzGerald and Sandra Tomek and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Journal of Clinical Oncology.

In The Last Decade

Michael Krainer

105 papers receiving 3.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Michael Krainer Austria 33 1.5k 1.4k 767 692 579 106 3.5k
Marco Danova Italy 30 1.6k 1.1× 1.1k 0.8× 520 0.7× 634 0.9× 277 0.5× 226 3.5k
Diane L. Persons United States 29 1.3k 0.9× 1.4k 1.0× 295 0.4× 608 0.9× 331 0.6× 64 3.1k
Barbara Schmalfeldt Germany 33 1.5k 1.0× 1.2k 0.8× 728 0.9× 855 1.2× 147 0.3× 130 4.2k
Paul Frankel United States 34 1.9k 1.3× 1.8k 1.2× 388 0.5× 658 1.0× 196 0.3× 214 4.1k
J Garcı́a-Conde Spain 35 2.0k 1.4× 954 0.7× 596 0.8× 584 0.8× 299 0.5× 104 3.9k
Gordana Vlahovic United States 26 2.2k 1.5× 920 0.6× 973 1.3× 454 0.7× 305 0.5× 93 3.9k
José A. Martínez-Climent Spain 39 1.3k 0.9× 1.9k 1.3× 509 0.7× 784 1.1× 354 0.6× 135 4.5k
Benjamin Esterni France 32 2.2k 1.5× 1.4k 1.0× 380 0.5× 1.0k 1.5× 213 0.4× 75 4.4k
Philippe Martiat Belgium 38 1.3k 0.9× 2.0k 1.4× 932 1.2× 1.5k 2.2× 415 0.7× 110 5.6k
Lia Gore United States 43 2.6k 1.8× 2.6k 1.8× 743 1.0× 632 0.9× 256 0.4× 202 6.1k

Countries citing papers authored by Michael Krainer

Since Specialization
Citations

This map shows the geographic impact of Michael Krainer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Krainer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Krainer more than expected).

Fields of papers citing papers by Michael Krainer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Krainer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Krainer. The network helps show where Michael Krainer may publish in the future.

Co-authorship network of co-authors of Michael Krainer

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Krainer. A scholar is included among the top collaborators of Michael Krainer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Krainer. Michael Krainer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Schuster, Eva, Michael Krainer, Maximilian Marhold, et al.. (2023). Comparison of RNA Marker Panels for Circulating Tumor Cells and Evaluation of Their Prognostic Relevance in Breast Cancer. Cancers. 15(4). 1271–1271. 7 indexed citations
2.
Marhold, Maximilian, Gero Kramer, Michael Krainer, & Clémentine Le Magnen. (2021). The prostate cancer landscape in Europe: Current challenges, future opportunities. Cancer Letters. 526. 304–310. 24 indexed citations
3.
Aust, Stefanie, Richard Schwameis, Leonhard Müllauer, et al.. (2020). Precision Medicine Tumor Boards: Clinical Applicability of Personalized Treatment Concepts in Ovarian Cancer. Cancers. 12(3). 548–548. 15 indexed citations
4.
5.
Schwameis, Richard, Christoph Grimm, Edgar Petru, et al.. (2015). The Prognostic Value of C-Reactive Protein Serum Levels in Patients with Uterine Leiomyosarcoma. PLoS ONE. 10(8). e0133838–e0133838. 10 indexed citations
6.
Marhold, Maximilian, Erwin Tomasich, Ahmed El‐Gazzar, et al.. (2014). HIF1α Regulates mTOR Signaling and Viability of Prostate Cancer Stem Cells. Molecular Cancer Research. 13(3). 556–564. 72 indexed citations
7.
Horak, Peter, Erwin Tomasich, Petr Vaňhara, et al.. (2014). TUSC3 Loss Alters the ER Stress Response and Accelerates Prostate Cancer Growth in vivo. Scientific Reports. 4(1). 3739–3739. 47 indexed citations
8.
Vaňhara, Petr, Ahmed El‐Gazzar, Dietmar Pils, et al.. (2011). hVps37A Status Affects Prognosis and Cetuximab Sensitivity in Ovarian Cancer. Clinical Cancer Research. 17(24). 7816–7827. 37 indexed citations
9.
El‐Gazzar, Ahmed, Paul Perco, Eva Eckelhart, et al.. (2010). Natural Immunity Enhances the Activity of a DR5 Agonistic Antibody and Carboplatin in the Treatment of Ovarian Cancer. Molecular Cancer Therapeutics. 9(4). 1007–1018. 16 indexed citations
10.
Li, Lin, Stephan Ryser, Éva Dizin, et al.. (2007). Oncogenic BARD1 Isoforms Expressed in Gynecological Cancers. Cancer Research. 67(24). 11876–11885. 51 indexed citations
11.
Horak, Peter, Dietmar Pils, Katarzyna Elandt, et al.. (2006). N33 (TUSC3) promoter hypermethylation in serum of prostate cancer patients. Cancer Research. 66. 763–764. 2 indexed citations
12.
Pils, Dietmar, Peter Horak, Andreas Gleiß, et al.. (2006). Hypermethylation of N33 (TUSC3) as independent molecular predictor for ovarian cancer. Cancer Research. 66. 760–760. 2 indexed citations
13.
Krainer, Michael, Gabriela Kornek, Gottfried J. Locker, et al.. (2005). Single-agent trastuzumab versus trastuzumab plus cytotoxic chemotherapy in metastatic breast cancer: a single-institution experience. Anti-Cancer Drugs. 16(2). 185–190. 3 indexed citations
14.
Köstler, Wolfgang J., Günther Steger, Afschin Soleiman, et al.. (2004). Monitoring of serum Her-2/neu predicts histopathological response to neoadjuvant trastuzumab-based therapy for breast cancer.. PubMed. 24(2C). 1127–30. 25 indexed citations
15.
Tomek, Sandra, Peter Horak, Ingrid Pribill, et al.. (2004). Resistance to TRAIL-induced apoptosis in ovarian cancer cell lines is overcome by co-treatment with cytotoxic drugs. Gynecologic Oncology. 94(1). 107–114. 50 indexed citations
16.
Köstler, Wolfgang J., Sandra Tomek, Thomas Brodowicz, et al.. (2001). Soluble ICAM-1 in breast cancer: clinical significance and biological implications. Cancer Immunology Immunotherapy. 50(9). 483–490. 21 indexed citations
17.
Stöger, Herbert, H. Samonigg, Michael Krainer, et al.. (1998). Dose intensification of epidoxorubicin and cyclophosphamide in metastatic breast cancer: a randomised study with two schedules of granulocyte-macrophage colony stimulating factor. European Journal of Cancer. 34(4). 482–488. 12 indexed citations
18.
Krainer, Michael, Thomas Brodowicz, Robert Zeillinger, et al.. (1997). Tissue Expression and Serum Levels of HER-2/neu in Patients with Breast Cancer. Oncology. 54(6). 475–481. 72 indexed citations
19.
Brodowicz, Thomas, Christoph Wiltschke, Alexandra C. Budinsky, et al.. (1997). Soluble HER-2/neu neutralizes biologic effects of anti-HER-2/neu antibody on breast cancer cellsin vitro. International Journal of Cancer. 73(6). 875–879. 66 indexed citations
20.
Budinsky, Alexandra C., et al.. (1997). Decreased expression of ICAM-1 and its induction by tumor necrosis factor on breast-cancer cellsin vitro. International Journal of Cancer. 71(6). 1086–1090. 30 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Marco Danova Breakdown of academic impact, for papers by Diane L. Persons Breakdown of academic impact, for papers by Barbara Schmalfeldt Breakdown of academic impact, for papers by Paul Frankel Breakdown of academic impact, for papers by J Garcı́a-Conde Breakdown of academic impact, for papers by Gordana Vlahovic Breakdown of academic impact, for papers by José A. Martínez-Climent Breakdown of academic impact, for papers by Benjamin Esterni Breakdown of academic impact, for papers by Philippe Martiat Breakdown of academic impact, for papers by Lia Gore
Rankless by CCL
2026